Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Vivasrenal

Phys Vivas · renal

Renal Cell Carcinoma AND Urothelial Malignancy — Viva Defence

DCE viva defence for Renal Cell Carcinoma AND Urothelial Malignancy.

1 min readVerification in progress

Target exams

FRACP DCEMRCP PACES
On this page
Study tools

Target exams

FRACP DCEMRCP PACES
Prompt
DCE viva defence for Renal Cell Carcinoma AND Urothelial Malignancy.

Renal Cell Carcinoma AND Urothelial Malignancy Viva

Long Case Viva Defence

Opening statement

"This patient presents with a problem best framed as Renal Cell Carcinoma AND Urothelial Malignancy. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]

Examiner questions

Q1: "What makes this urgent?" [1]

"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]

Q2: "What is your first investigation package?" [2]

"I order tests that change management now, not a scattergun panel." [1] [2]

Q3: "Walk me through treatment." [1]

"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]

Q4: "What is the classic trap?" [2]

"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]

Physician Medicine Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References6ShowHide
  1. [1]Chen YS, Yu CC, Chang R, Wu SH, et al. Efficacy of checkpoint inhibitors in genitourinary cancers with advanced chronic kidney disease Cancer Immunol Immunother, 2026.PMID 42426360
  2. [2]Petrelli F, Colombo Zefinetti L, D'Alessio A, Dottorini L, et al. Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings Curr Oncol Rep, 2026.PMID 42406187
  3. [3]Zhang Y, Wu G, Sun F, Wang B, et al. Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making Front Oncol, 2026.PMID 42404222
  4. [4]Jost LM, Duwe G, Kauth V, Höfner T, et al. [Artificial intelligence as decision support tool in urological oncology: current evidence and challenges] Urologie, 2026.PMID 42126599
  5. [5]Inoue S, Tsuboi I, Miszczyk M, Miyajima K, et al. Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis JAMA Netw Open, 2026.PMID 42084869
  6. [6]Maráz A, Koroncziová K, Rozsvai T [Immunotherapy for urological cancers in 2025] Magy Onkol, 2025.PMID 41385769
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPotassium Disorders — Viva DefencerenalNextRenal Replacement Therapy (Haemodialysis, Peritoneal Dialysis) — Viva Defencerenal